NASDAQ:HRTX

Heron Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy HRTX

*Your capital is at risk

$0.496

-0.0012 (-0.241%)

At Close: Jul 31, 2026

Heron Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.99. In total, the insiders bought 14.27M and sold 100.37K HRTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.99
● Buy	14.27M shares
● Sell	100.37K shares
96% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 19, 2025 Buy	Restricted Stock Units M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	3 874 Value: $2K
Oct 19, 2025 Buy	Common Stock M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	13 797 Value: $7K
Oct 19, 2025 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	13 797 Value: $7K
Oct 15, 2025 Sell	Series A Convertible Preferred Stock ("Preferred Shares") C-Conversion	Rubric Capital Management Lp 10 Percent Owner	10% Owner	94 610 Value: $0
Oct 15, 2025 Buy	Common Stock, par value $0.01 per share ("Common Stock") C-Conversion	Rubric Capital Management Lp 10 Percent Owner	10% Owner	946 100 Value: $1.28M
Aug 08, 2025 Buy	Common Stock, par value $0.01 per share ("Common Stock") P-Purchase	Rubric Capital Management Lp 10 Percent Owner	10% Owner	2 387 225 Value: $3.58M
Aug 08, 2025 Buy	Series A Convertible Preferred Stock ("Preferred Shares") P-Purchase	Rubric Capital Management Lp 10 Percent Owner	10% Owner	94 610 Value: $124.9K
Aug 08, 2025 Buy	Convertible Senior Unsecured Promissory Notes ("Notes") P-Purchase	Rubric Capital Management Lp 10 Percent Owner	10% Owner	0 Value: $0
Aug 08, 2025 Buy	Common Stock P-Purchase	Morgan Adam Director	Director	1 766 546 Value: $2.65M
Aug 08, 2025 Buy	Series A Convertible Preferred Stock P-Purchase	Morgan Adam Director	Director	70 012 Value: $105.0K
Aug 08, 2025 Buy	Series A Convertible Preferred Stock P-Purchase	Morgan Adam Director	Director	70 012 Value: $105.0K
Aug 08, 2025 Buy	Common Stock P-Purchase	Morgan Adam Director	Director	1 766 546 Value: $2.65M
Aug 08, 2025 Buy	Convertible Senior Unsecured Promissory Notes ("Notes") P-Purchase	Rubric Capital Management Lp 10 Percent Owner	10% Owner	0 Value: $0
Aug 08, 2025 Buy	Series A Convertible Preferred Stock ("Preferred Shares") P-Purchase	Rubric Capital Management Lp 10 Percent Owner	10% Owner	94 610 Value: $124.9K
Aug 08, 2025 Buy	Common Stock, par value $0.01 per share ("Common Stock") P-Purchase	Rubric Capital Management Lp 10 Percent Owner	10% Owner	2 387 225 Value: $3.58M
Jul 31, 2025 Buy	Restricted Stock Units M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 695 Value: $20.2K
Jul 31, 2025 Buy	Common Stock M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 695 Value: $20.2K
Jul 31, 2025 Buy	Common Stock M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 695 Value: $20.2K
Jul 31, 2025 Buy	Restricted Stock Units M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 695 Value: $20.2K
Jul 31, 2025 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	34 789 Value: $60.2K
Jul 31, 2025 Buy	Common Stock M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	34 789 Value: $60.2K
Jul 31, 2025 Buy	Restricted Stock Units M-Exempt	Collard Craig A Chief Executive Officer	CEO / President	34 789 Value: $60.2K
Jul 31, 2025 Buy	Restricted Stock Units M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 695 Value: $20.2K
Jul 31, 2025 Buy	Common Stock M-Exempt	Duarte Ira EVP, Chief Financial Officer	C-Suite Officer	11 695 Value: $20.2K
Jul 31, 2025 Buy	Common Stock M-Exempt	Forbes William P EVP, Chief Development Officer	Officer	11 695 Value: $20.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT HERON THERAPEUTICS

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...

Read Full Profile Here